Quality of FDM 3D Printed Medicines for Pediatrics: Considerations for Formulation Development, Filament Extrusion, Printing Process and Printer Design
3d printing is capable of providing dose individualization for pediatric medicines and translating the precision medicine approach into practical application. In pediatrics, dose individualization and preparation of small dosage forms is a requirement for successful therapy, which is frequently not...
Gespeichert in:
Veröffentlicht in: | Therapeutic innovation & regulatory science 2022-11, Vol.56 (6), p.910-928 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 928 |
---|---|
container_issue | 6 |
container_start_page | 910 |
container_title | Therapeutic innovation & regulatory science |
container_volume | 56 |
creator | Quodbach, Julian Bogdahn, Malte Breitkreutz, Jörg Chamberlain, Rebecca Eggenreich, Karin Elia, Alessandro Giuseppe Gottschalk, Nadine Gunkel-Grabole, Gesine Hoffmann, Lena Kapote, Dnyaneshwar Kipping, Thomas Klinken, Stefan Loose, Fabian Marquetant, Tristan Windolf, Hellen Geißler, Simon Spitz, Tilmann |
description | 3d printing is capable of providing dose individualization for pediatric medicines and translating the precision medicine approach into practical application. In pediatrics, dose individualization and preparation of small dosage forms is a requirement for successful therapy, which is frequently not possible due to the lack of suitable dosage forms. For precision medicine, individual characteristics of patients are considered for the selection of the best possible API in the most suitable dose with the most effective release profile to improve therapeutic outcome. 3d printing is inherently suitable for manufacturing of individualized medicines with varying dosages, sizes, release profiles and drug combinations in small batch sizes, which cannot be manufactured with traditional technologies. However, understanding of critical quality attributes and process parameters still needs to be significantly improved for this new technology. To ensure health and safety of patients, cleaning and process validation needs to be established. Additionally, adequate analytical methods for the in-process control of intermediates, regarding their printability as well as control of the final 3d printed tablets considering any risk of this new technology will be required. The PolyPrint consortium is actively working on developing novel polymers for fused deposition modeling (FDM) 3d printing, filament formulation and manufacturing development as well as optimization of the printing process, and the design of a GMP-capable FDM 3d printer. In this manuscript, the consortium shares its views on quality aspects and measures for 3d printing from drug-loaded filaments, including formulation development, the printing process, and the printed dosage forms. Additionally, engineering approaches for quality assurance during the printing process and for the final dosage form will be presented together with considerations for a GMP-capable printer design. |
doi_str_mv | 10.1007/s43441-021-00354-0 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9492703</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2716550096</sourcerecordid><originalsourceid>FETCH-LOGICAL-c451t-ca18e5b407120b4cc0d53dc1f1daf2f2ed63ac4cd9a33b623c3f11e1d42682d63</originalsourceid><addsrcrecordid>eNp9UctOAyEUJUajjfYHXJG47SivebkwMX2oSY2a6JpQYCpmChVmGvsl_q60UzVuJCEcOPecCxwATjE6xwjlF4FRxnCCSJyIpixBe6BHcFYkrEBs_xvnJToC_RDeUBxlkeakOARHlBUkwwT1wOdTK2rTrKGr4GR0D-kIPnpjG63gvVZGGqsDrJyHj3EnGm9kuIRDZ4NR2ovGRLSlJ84v2np7AEd6pWu3XGjbDODE1GKD4Pij8W2I_KDrYOw8Aid1CFBYtWvrozqYuT0BB5Wog-7v1mPwMhk_D2-T6cPN3fB6mkiW4iaRAhc6nTGUx9fMmJRIpVRJXGElKlIRrTIqJJOqFJTOMkIlrTDWWDGSFSSSx-Cq8122s4VWMt7Ui5ovvVkIv-ZOGP6XseaVz92Kl6wkOaLR4Gxn4N17q0PD31zrbbwzJznO0jR--6YN6aqkdyF4Xf10wIhv8uRdnjzmybd5chRFtBOFWGzn2v9a_6P6AtjRpJU</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2716550096</pqid></control><display><type>article</type><title>Quality of FDM 3D Printed Medicines for Pediatrics: Considerations for Formulation Development, Filament Extrusion, Printing Process and Printer Design</title><source>SpringerLink Journals - AutoHoldings</source><creator>Quodbach, Julian ; Bogdahn, Malte ; Breitkreutz, Jörg ; Chamberlain, Rebecca ; Eggenreich, Karin ; Elia, Alessandro Giuseppe ; Gottschalk, Nadine ; Gunkel-Grabole, Gesine ; Hoffmann, Lena ; Kapote, Dnyaneshwar ; Kipping, Thomas ; Klinken, Stefan ; Loose, Fabian ; Marquetant, Tristan ; Windolf, Hellen ; Geißler, Simon ; Spitz, Tilmann</creator><creatorcontrib>Quodbach, Julian ; Bogdahn, Malte ; Breitkreutz, Jörg ; Chamberlain, Rebecca ; Eggenreich, Karin ; Elia, Alessandro Giuseppe ; Gottschalk, Nadine ; Gunkel-Grabole, Gesine ; Hoffmann, Lena ; Kapote, Dnyaneshwar ; Kipping, Thomas ; Klinken, Stefan ; Loose, Fabian ; Marquetant, Tristan ; Windolf, Hellen ; Geißler, Simon ; Spitz, Tilmann</creatorcontrib><description>3d printing is capable of providing dose individualization for pediatric medicines and translating the precision medicine approach into practical application. In pediatrics, dose individualization and preparation of small dosage forms is a requirement for successful therapy, which is frequently not possible due to the lack of suitable dosage forms. For precision medicine, individual characteristics of patients are considered for the selection of the best possible API in the most suitable dose with the most effective release profile to improve therapeutic outcome. 3d printing is inherently suitable for manufacturing of individualized medicines with varying dosages, sizes, release profiles and drug combinations in small batch sizes, which cannot be manufactured with traditional technologies. However, understanding of critical quality attributes and process parameters still needs to be significantly improved for this new technology. To ensure health and safety of patients, cleaning and process validation needs to be established. Additionally, adequate analytical methods for the in-process control of intermediates, regarding their printability as well as control of the final 3d printed tablets considering any risk of this new technology will be required. The PolyPrint consortium is actively working on developing novel polymers for fused deposition modeling (FDM) 3d printing, filament formulation and manufacturing development as well as optimization of the printing process, and the design of a GMP-capable FDM 3d printer. In this manuscript, the consortium shares its views on quality aspects and measures for 3d printing from drug-loaded filaments, including formulation development, the printing process, and the printed dosage forms. Additionally, engineering approaches for quality assurance during the printing process and for the final dosage form will be presented together with considerations for a GMP-capable printer design.</description><identifier>ISSN: 2168-4790</identifier><identifier>EISSN: 2168-4804</identifier><identifier>DOI: 10.1007/s43441-021-00354-0</identifier><identifier>PMID: 34826120</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>3-D printers ; Analytical methods ; Consortia ; Design ; Dosage ; Drug dosages ; Drug Safety and Pharmacovigilance ; Extrusion ; Filaments ; Fused deposition modeling ; Intermediates ; Manufacturing ; Medicine ; New technology ; Optimization ; Patients ; Pediatrics ; Pharmacotherapy ; Pharmacy ; Polymers ; Precision medicine ; Printing ; Process control ; Process controls ; Process parameters ; Quality assurance ; Quality management ; Review ; Three dimensional printing</subject><ispartof>Therapeutic innovation & regulatory science, 2022-11, Vol.56 (6), p.910-928</ispartof><rights>The Author(s) 2021</rights><rights>The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c451t-ca18e5b407120b4cc0d53dc1f1daf2f2ed63ac4cd9a33b623c3f11e1d42682d63</citedby><cites>FETCH-LOGICAL-c451t-ca18e5b407120b4cc0d53dc1f1daf2f2ed63ac4cd9a33b623c3f11e1d42682d63</cites><orcidid>0000-0003-2471-4502</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s43441-021-00354-0$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s43441-021-00354-0$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,27924,27925,41488,42557,51319</link.rule.ids></links><search><creatorcontrib>Quodbach, Julian</creatorcontrib><creatorcontrib>Bogdahn, Malte</creatorcontrib><creatorcontrib>Breitkreutz, Jörg</creatorcontrib><creatorcontrib>Chamberlain, Rebecca</creatorcontrib><creatorcontrib>Eggenreich, Karin</creatorcontrib><creatorcontrib>Elia, Alessandro Giuseppe</creatorcontrib><creatorcontrib>Gottschalk, Nadine</creatorcontrib><creatorcontrib>Gunkel-Grabole, Gesine</creatorcontrib><creatorcontrib>Hoffmann, Lena</creatorcontrib><creatorcontrib>Kapote, Dnyaneshwar</creatorcontrib><creatorcontrib>Kipping, Thomas</creatorcontrib><creatorcontrib>Klinken, Stefan</creatorcontrib><creatorcontrib>Loose, Fabian</creatorcontrib><creatorcontrib>Marquetant, Tristan</creatorcontrib><creatorcontrib>Windolf, Hellen</creatorcontrib><creatorcontrib>Geißler, Simon</creatorcontrib><creatorcontrib>Spitz, Tilmann</creatorcontrib><title>Quality of FDM 3D Printed Medicines for Pediatrics: Considerations for Formulation Development, Filament Extrusion, Printing Process and Printer Design</title><title>Therapeutic innovation & regulatory science</title><addtitle>Ther Innov Regul Sci</addtitle><description>3d printing is capable of providing dose individualization for pediatric medicines and translating the precision medicine approach into practical application. In pediatrics, dose individualization and preparation of small dosage forms is a requirement for successful therapy, which is frequently not possible due to the lack of suitable dosage forms. For precision medicine, individual characteristics of patients are considered for the selection of the best possible API in the most suitable dose with the most effective release profile to improve therapeutic outcome. 3d printing is inherently suitable for manufacturing of individualized medicines with varying dosages, sizes, release profiles and drug combinations in small batch sizes, which cannot be manufactured with traditional technologies. However, understanding of critical quality attributes and process parameters still needs to be significantly improved for this new technology. To ensure health and safety of patients, cleaning and process validation needs to be established. Additionally, adequate analytical methods for the in-process control of intermediates, regarding their printability as well as control of the final 3d printed tablets considering any risk of this new technology will be required. The PolyPrint consortium is actively working on developing novel polymers for fused deposition modeling (FDM) 3d printing, filament formulation and manufacturing development as well as optimization of the printing process, and the design of a GMP-capable FDM 3d printer. In this manuscript, the consortium shares its views on quality aspects and measures for 3d printing from drug-loaded filaments, including formulation development, the printing process, and the printed dosage forms. Additionally, engineering approaches for quality assurance during the printing process and for the final dosage form will be presented together with considerations for a GMP-capable printer design.</description><subject>3-D printers</subject><subject>Analytical methods</subject><subject>Consortia</subject><subject>Design</subject><subject>Dosage</subject><subject>Drug dosages</subject><subject>Drug Safety and Pharmacovigilance</subject><subject>Extrusion</subject><subject>Filaments</subject><subject>Fused deposition modeling</subject><subject>Intermediates</subject><subject>Manufacturing</subject><subject>Medicine</subject><subject>New technology</subject><subject>Optimization</subject><subject>Patients</subject><subject>Pediatrics</subject><subject>Pharmacotherapy</subject><subject>Pharmacy</subject><subject>Polymers</subject><subject>Precision medicine</subject><subject>Printing</subject><subject>Process control</subject><subject>Process controls</subject><subject>Process parameters</subject><subject>Quality assurance</subject><subject>Quality management</subject><subject>Review</subject><subject>Three dimensional printing</subject><issn>2168-4790</issn><issn>2168-4804</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><recordid>eNp9UctOAyEUJUajjfYHXJG47SivebkwMX2oSY2a6JpQYCpmChVmGvsl_q60UzVuJCEcOPecCxwATjE6xwjlF4FRxnCCSJyIpixBe6BHcFYkrEBs_xvnJToC_RDeUBxlkeakOARHlBUkwwT1wOdTK2rTrKGr4GR0D-kIPnpjG63gvVZGGqsDrJyHj3EnGm9kuIRDZ4NR2ovGRLSlJ84v2np7AEd6pWu3XGjbDODE1GKD4Pij8W2I_KDrYOw8Aid1CFBYtWvrozqYuT0BB5Wog-7v1mPwMhk_D2-T6cPN3fB6mkiW4iaRAhc6nTGUx9fMmJRIpVRJXGElKlIRrTIqJJOqFJTOMkIlrTDWWDGSFSSSx-Cq8122s4VWMt7Ui5ovvVkIv-ZOGP6XseaVz92Kl6wkOaLR4Gxn4N17q0PD31zrbbwzJznO0jR--6YN6aqkdyF4Xf10wIhv8uRdnjzmybd5chRFtBOFWGzn2v9a_6P6AtjRpJU</recordid><startdate>20221101</startdate><enddate>20221101</enddate><creator>Quodbach, Julian</creator><creator>Bogdahn, Malte</creator><creator>Breitkreutz, Jörg</creator><creator>Chamberlain, Rebecca</creator><creator>Eggenreich, Karin</creator><creator>Elia, Alessandro Giuseppe</creator><creator>Gottschalk, Nadine</creator><creator>Gunkel-Grabole, Gesine</creator><creator>Hoffmann, Lena</creator><creator>Kapote, Dnyaneshwar</creator><creator>Kipping, Thomas</creator><creator>Klinken, Stefan</creator><creator>Loose, Fabian</creator><creator>Marquetant, Tristan</creator><creator>Windolf, Hellen</creator><creator>Geißler, Simon</creator><creator>Spitz, Tilmann</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U7</scope><scope>C1K</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-2471-4502</orcidid></search><sort><creationdate>20221101</creationdate><title>Quality of FDM 3D Printed Medicines for Pediatrics: Considerations for Formulation Development, Filament Extrusion, Printing Process and Printer Design</title><author>Quodbach, Julian ; Bogdahn, Malte ; Breitkreutz, Jörg ; Chamberlain, Rebecca ; Eggenreich, Karin ; Elia, Alessandro Giuseppe ; Gottschalk, Nadine ; Gunkel-Grabole, Gesine ; Hoffmann, Lena ; Kapote, Dnyaneshwar ; Kipping, Thomas ; Klinken, Stefan ; Loose, Fabian ; Marquetant, Tristan ; Windolf, Hellen ; Geißler, Simon ; Spitz, Tilmann</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c451t-ca18e5b407120b4cc0d53dc1f1daf2f2ed63ac4cd9a33b623c3f11e1d42682d63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>3-D printers</topic><topic>Analytical methods</topic><topic>Consortia</topic><topic>Design</topic><topic>Dosage</topic><topic>Drug dosages</topic><topic>Drug Safety and Pharmacovigilance</topic><topic>Extrusion</topic><topic>Filaments</topic><topic>Fused deposition modeling</topic><topic>Intermediates</topic><topic>Manufacturing</topic><topic>Medicine</topic><topic>New technology</topic><topic>Optimization</topic><topic>Patients</topic><topic>Pediatrics</topic><topic>Pharmacotherapy</topic><topic>Pharmacy</topic><topic>Polymers</topic><topic>Precision medicine</topic><topic>Printing</topic><topic>Process control</topic><topic>Process controls</topic><topic>Process parameters</topic><topic>Quality assurance</topic><topic>Quality management</topic><topic>Review</topic><topic>Three dimensional printing</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Quodbach, Julian</creatorcontrib><creatorcontrib>Bogdahn, Malte</creatorcontrib><creatorcontrib>Breitkreutz, Jörg</creatorcontrib><creatorcontrib>Chamberlain, Rebecca</creatorcontrib><creatorcontrib>Eggenreich, Karin</creatorcontrib><creatorcontrib>Elia, Alessandro Giuseppe</creatorcontrib><creatorcontrib>Gottschalk, Nadine</creatorcontrib><creatorcontrib>Gunkel-Grabole, Gesine</creatorcontrib><creatorcontrib>Hoffmann, Lena</creatorcontrib><creatorcontrib>Kapote, Dnyaneshwar</creatorcontrib><creatorcontrib>Kipping, Thomas</creatorcontrib><creatorcontrib>Klinken, Stefan</creatorcontrib><creatorcontrib>Loose, Fabian</creatorcontrib><creatorcontrib>Marquetant, Tristan</creatorcontrib><creatorcontrib>Windolf, Hellen</creatorcontrib><creatorcontrib>Geißler, Simon</creatorcontrib><creatorcontrib>Spitz, Tilmann</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>CrossRef</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Therapeutic innovation & regulatory science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Quodbach, Julian</au><au>Bogdahn, Malte</au><au>Breitkreutz, Jörg</au><au>Chamberlain, Rebecca</au><au>Eggenreich, Karin</au><au>Elia, Alessandro Giuseppe</au><au>Gottschalk, Nadine</au><au>Gunkel-Grabole, Gesine</au><au>Hoffmann, Lena</au><au>Kapote, Dnyaneshwar</au><au>Kipping, Thomas</au><au>Klinken, Stefan</au><au>Loose, Fabian</au><au>Marquetant, Tristan</au><au>Windolf, Hellen</au><au>Geißler, Simon</au><au>Spitz, Tilmann</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Quality of FDM 3D Printed Medicines for Pediatrics: Considerations for Formulation Development, Filament Extrusion, Printing Process and Printer Design</atitle><jtitle>Therapeutic innovation & regulatory science</jtitle><stitle>Ther Innov Regul Sci</stitle><date>2022-11-01</date><risdate>2022</risdate><volume>56</volume><issue>6</issue><spage>910</spage><epage>928</epage><pages>910-928</pages><issn>2168-4790</issn><eissn>2168-4804</eissn><abstract>3d printing is capable of providing dose individualization for pediatric medicines and translating the precision medicine approach into practical application. In pediatrics, dose individualization and preparation of small dosage forms is a requirement for successful therapy, which is frequently not possible due to the lack of suitable dosage forms. For precision medicine, individual characteristics of patients are considered for the selection of the best possible API in the most suitable dose with the most effective release profile to improve therapeutic outcome. 3d printing is inherently suitable for manufacturing of individualized medicines with varying dosages, sizes, release profiles and drug combinations in small batch sizes, which cannot be manufactured with traditional technologies. However, understanding of critical quality attributes and process parameters still needs to be significantly improved for this new technology. To ensure health and safety of patients, cleaning and process validation needs to be established. Additionally, adequate analytical methods for the in-process control of intermediates, regarding their printability as well as control of the final 3d printed tablets considering any risk of this new technology will be required. The PolyPrint consortium is actively working on developing novel polymers for fused deposition modeling (FDM) 3d printing, filament formulation and manufacturing development as well as optimization of the printing process, and the design of a GMP-capable FDM 3d printer. In this manuscript, the consortium shares its views on quality aspects and measures for 3d printing from drug-loaded filaments, including formulation development, the printing process, and the printed dosage forms. Additionally, engineering approaches for quality assurance during the printing process and for the final dosage form will be presented together with considerations for a GMP-capable printer design.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>34826120</pmid><doi>10.1007/s43441-021-00354-0</doi><tpages>19</tpages><orcidid>https://orcid.org/0000-0003-2471-4502</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2168-4790 |
ispartof | Therapeutic innovation & regulatory science, 2022-11, Vol.56 (6), p.910-928 |
issn | 2168-4790 2168-4804 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9492703 |
source | SpringerLink Journals - AutoHoldings |
subjects | 3-D printers Analytical methods Consortia Design Dosage Drug dosages Drug Safety and Pharmacovigilance Extrusion Filaments Fused deposition modeling Intermediates Manufacturing Medicine New technology Optimization Patients Pediatrics Pharmacotherapy Pharmacy Polymers Precision medicine Printing Process control Process controls Process parameters Quality assurance Quality management Review Three dimensional printing |
title | Quality of FDM 3D Printed Medicines for Pediatrics: Considerations for Formulation Development, Filament Extrusion, Printing Process and Printer Design |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T15%3A43%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Quality%20of%20FDM%203D%20Printed%20Medicines%20for%20Pediatrics:%20Considerations%20for%20Formulation%20Development,%20Filament%20Extrusion,%20Printing%20Process%20and%20Printer%20Design&rft.jtitle=Therapeutic%20innovation%20&%20regulatory%20science&rft.au=Quodbach,%20Julian&rft.date=2022-11-01&rft.volume=56&rft.issue=6&rft.spage=910&rft.epage=928&rft.pages=910-928&rft.issn=2168-4790&rft.eissn=2168-4804&rft_id=info:doi/10.1007/s43441-021-00354-0&rft_dat=%3Cproquest_pubme%3E2716550096%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2716550096&rft_id=info:pmid/34826120&rfr_iscdi=true |